| Thirty-fifth Patient Enrolled In The NeuroVasx CPAX Aneurysm Treatment System Clinical Study |
|
| From:medicalnewstoday.com Hits: Update:2006-12-13 22:26:07 |
NeuroVasx, Inc. is
developing its cPAX aneurysm Treatment System to meet the need for a
better, more cost effective solution for the minimally invasive treatment
of cerebral aneurysms. A cerebral aneurysm is an abnormal bulge or sac in
the wall of an artery in the brain. If ruptured, the aneurysm can result in
massive intracranial bleeding and often lead to death.
The NeuroVasx Clinical Study, based in South America, will be a
critical component to the company's 510(k) Application to the FDA, which
they intend to submit in early 2007. Eric Timko, President and CEO of
NeuroVasx, Inc. stated, "The enrollment of the thirty-fifth patient in our
clinical study is a major achievement for our team at NeuroVasx. It brings
us one step closer to our 510(k) submission, a critical milestone for the
company."
About NeuroVasx, Inc
NeuroVasx, Inc. (http://www.neurovasx.com) is a privately held
medical device company located in Maple Grove, MN. The company is dedicated
to the development and commercialization of technologies for the
endovascular treatment of hemorrhagic and ischemic stroke.
NeuroVasx, Inc.
http://www.neurovasx.com
|
| |
| 【Forum】【Blog】【Fonts：Smaller Bigger】 |
